Europe Gastroparesis Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. Europe Gastroparesis Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Europe Gastroparesis Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. Europe Gastroparesis Market Regional Analysis

6.2 Europe Gastroparesis Market Revenue 2018-2027 (US$ Million)

6.3 Europe Gastroparesis Market Forecast Analysis

7. Europe Gastroparesis Market Analysis – by Type

7.1 Idiopathic

7.1.1 Overview
7.1.2 Idiopathic: Europe Gastroparesis Market – Revenue and Forecast, 2018-2027 (US$ Million)

7.2 Diabetic

7.2.1 Overview
7.2.2 Diabetic: Europe Gastroparesis Market – Revenue and Forecast, 2018-2027 (US$ Million)

7.3 Post-Surgical

7.3.1 Overview
7.3.2 Post-Surgical: Europe Gastroparesis Market – Revenue and Forecast, 2018-2027 (US$ Million)

8. Europe Gastroparesis Market Analysis – by Drug Class

8.1 Prokinetic Agents

8.1.1 Overview
8.1.2 Prokinetic Agents: Europe Gastroparesis Market – Revenue and Forecast, 2018-2027 (US$ Million)

8.2 Botulinum Toxin Injections

8.2.1 Overview
8.2.2 Botulinum Toxin Injections: Europe Gastroparesis Market – Revenue and Forecast, 2018-2027 (US$ Million)

8.3 Antiemetic Agents

8.3.1 Overview
8.3.2 Antiemetic Agents: Europe Gastroparesis Market – Revenue and Forecast, 2018-2027 (US$ Million)

9. Europe Gastroparesis Market Analysis – by Distribution Channel

9.1 Retail Pharmacies

9.1.1 Overview
9.1.2 Retail Pharmacies: Europe Gastroparesis Market – Revenue and Forecast, 2018-2027 (US$ Million)

9.2 Hospital Pharmacies

9.2.1 Overview
9.2.2 Hospital Pharmacies: Europe Gastroparesis Market – Revenue and Forecast, 2018-2027 (US$ Million)

10. Europe Gastroparesis Market – Europe Analysis

10.1 Overview

10.2 Europe

10.2.1 Europe Gastroparesis Market Breakdown, by Key Country, 2021 and 2027 (%)
10.2.1.1 Europe Gastroparesis Market – Revenue and Forecast Analysis – by Country
10.2.1.1 UK: Europe Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.1.1 UK: Europe Gastroparesis Market Breakdown, by Type
10.2.1.1.2 UK: Europe Gastroparesis Market Breakdown, by Drug Class
10.2.1.1.3 UK: Europe Gastroparesis Market Breakdown, by Distribution Channel

10.2.1.2 Germany: Europe Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.2.1 Germany: Europe Gastroparesis Market Breakdown, by Type
10.2.1.2.2 Germany: Europe Gastroparesis Market Breakdown, by Drug Class
10.2.1.2.3 Germany: Europe Gastroparesis Market Breakdown, by Distribution Channel

10.2.1.3 France: Europe Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.3.1 France: Europe Gastroparesis Market Breakdown, by Type
10.2.1.3.2 France: Europe Gastroparesis Market Breakdown, by Drug Class
10.2.1.3.3 France: Europe Gastroparesis Market Breakdown, by Distribution Channel

10.2.1.4 Russia: Europe Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.4.1 Russia: Europe Gastroparesis Market Breakdown, by Type
10.2.1.4.2 Russia: Europe Gastroparesis Market Breakdown, by Drug Class
10.2.1.4.3 Russia: Europe Gastroparesis Market Breakdown, by Distribution Channel

10.2.1.5 Italy: Europe Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.5.1 Italy: Europe Gastroparesis Market Breakdown, by Type
10.2.1.5.2 Italy: Europe Gastroparesis Market Breakdown, by Drug Class
10.2.1.5.3 Italy: Europe Gastroparesis Market Breakdown, by Distribution Channel

10.2.1.6 Rest of Europe: Europe Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.6.1 Rest of Europe: Europe Gastroparesis Market Breakdown, by Type
10.2.1.6.2 Rest of Europe: Europe Gastroparesis Market Breakdown, by Drug Class
10.2.1.6.3 Rest of Europe: Europe Gastroparesis Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Industry Landscape

12.1 Overview

12.2 Market Initiative

12.3 Partnerships and Collaborations

12.4 Other Developments

13. Company Profiles

13.1 Allergan Plc

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Ipca Laboratories Ltd.

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Johnson and Johnson Services, Inc.

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Pfizer Inc.

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 TEVA PHARMACEUTICAL INDUSTRIES LTD

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

14. Appendix

14.1 About Business Market Insights

14.2 List of Abbreviations

Europe Gastroparesis Market

Analysis By Type (Idiopathic, Diabetic, Post-Surgical, and Others), Drug Class (Prokinetic Agents, Botulinum Toxin Injections, and Antiemetic Agents), and Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others)